LIGAND PHARMACEUTICALS INC Quarterly Operating Income (Loss) in USD from Q2 2010 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Ligand Pharmaceuticals Inc quarterly/annual Operating Income (Loss) history and growth rate from Q2 2010 to Q4 2024.
  • Ligand Pharmaceuticals Inc Operating Income (Loss) for the quarter ending December 31, 2024 was -$9.64M, a 187% decline year-over-year.
  • Ligand Pharmaceuticals Inc Operating Income (Loss) for the twelve months ending December 31, 2024 was -$22.6M, a 289% decline year-over-year.
  • Ligand Pharmaceuticals Inc annual Operating Income (Loss) for 2024 was -$22.6M, a 289% decline from 2023.
  • Ligand Pharmaceuticals Inc annual Operating Income (Loss) for 2023 was $11.9M, a 293% increase from 2022.
  • Ligand Pharmaceuticals Inc annual Operating Income (Loss) for 2022 was $3.04M, a 97.1% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.